Welcome to LookChem.com Sign In|Join Free
  • or
HENAN SUNLAKE ENTERPRISE CORPORATION231277-92-2 for antineoplastic, tyrosine kinase inhibitor with stable stock//file1.lookchem.com/cas/reactions/2021/06/01/10502247.png
qq

Communicate with Supplier:

Ms. summer
Ms. summer: What can I do for you?

231277-92-2 for antineoplastic, tyrosine kinase inhibitor with stable stock CAS NO.231277-92-2

FOB Price:
USD 750.00-850.00 /Kilogram Get Latest Price
Min.Order Quantity:
1 Kilogram
Purity:
98% purity
Port:
China main ports
Payment Terms:
L/C,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

  • Offer CAS.NO: 231277-92-2 Lapatinib from own lab
  • Supply 231277-92-2 Lapatinib with best price
  • Sale 231277-92-2 Lapatinib for Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.

Quick Details

  • ProName: 231277-92-2 for antineoplastic, tyrosi...
  • CasNo: 231277-92-2
  • Molecular Formula: C29H26ClFN4O4S
  • Appearance: white crystalline powder
  • Application: 231277-92-2 Usage Lapatinib Ditosylat...
  • DeliveryTime: Within 7 working days since received y...
  • PackAge: 1g;5g;10g;25g;50g;100g;500g;1KG;5KG or...
  • Port: China main ports
  • ProductionCapacity: 50 Kilogram/Month
  • Purity: 98% purity
  • Storage: Room temperature with sealed well
  • Transportation: BY SEA /BY AIR /BY COURIER
  • LimitNum: 1 Kilogram
  • Usage: Lapatinib Ditosylate (GW572016, GW2016...
  • Valid Period: 6 month
  • Certification: ISO/9001 Certificate

Superiority

1. iso 9001 approved, gmp producing standard,proffesional qa system, our quality is guaranteed.

2. facotory direct sale, most comptive price ensured;

3. audited supplier on lookchem, no trick, no scam!

4. enough stock can make sure safe delivery.

5. complete before and after sale service, welcome your questions and glad to help.

lapatinib
cas no: 231277-92-2
purity: ≥98%
structure type: lapatinib

Details

lapatinib
cas no: 231277-92-2
purity: ≥98%
structure type: lapatinib
lapatinib basic information
new drugs targeted therapy in breast cancer
product name: lapatinib
synonyms: lapatinib;n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;4-quinazolinamine, n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-;lapatinib(tinibs);n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;lapatinib base n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine;n-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
cas: 231277-92-2
mf: c29h26clfn4o4s
mw: 581.0575432
einecs:
product categories: molecular targeted antineoplastic;anti-neoplastic;pharmaceutical intermediate;apis;api;lapatinib;anti-cancer&immunity;inhibitors
mol file: 231277-92-2.mol
lapatinib structure
lapatinib chemical properties
cas database reference 231277-92-2(cas database reference)
safety information
msds information
lapatinib usage and synthesis
new drugs targeted therapy in breast cancer lapatinib is developed by the british company glaxosmithkline,it is a breast cancer targeted therapy drug,it is a tyrosine kinase inhibitor, which can inhibit the human epidermal growth factor receptor -1 (erbb1) and human epidermal growth factor receptor -2 (erbb2) tyrosine kinase activity. it is unique because it can play a role in a variety of ways, so that the breast cancer cells can not receive the desired signal for the growth . the mechanism is inhibiting the atp site of intracellular egfr(erbb-1) and her2 (erbb-2) to prevent phosphorylation and activation of tumor cells, blocking down signal by egfr (erbb-1) and homogenous her2 (erbb-1) and its heterodimer.
breast cancer molecular targeted therapy aims at the occurrence and development of cancer-related genes and their expression products of breast cancer for treatment. molecular targeted drugs by blocking signal transduction of tumor cells or associated cells , control changes in cell gene expression, in order to inhibit or kill tumor cells.
march 14, 2007, the us food and drug administration approved lapatinib in combination with xeloda (capecitabine) for the treatment of human epidermal factor receptor 2 (erbb2) overexpression and treated by anthracyclines, paclitaxel and trastuzumab patients with advanced or metastatic breast cancer.
clinical trials have shown that for those her2 type breast cancer patients who are resistant to roche's herceptin , the product also has very good clinical results.
lapatinib is a novel targeted anti-cancer drug. it can act on her-1 and her-2 two targets at he same time, the biological effect of the inhibition of tumor cell proliferation and growth arising from this mode of action is much larger than acting on just one target. the so-called targeted therapy, refers to certain receptors, genes or proteins as a key target, and then targets to kill tumor cells related to drugs.
human erbb receptors belong to the type i receptor tyrosine kinase (tk) family. it includes erbb1 (egfr), erbb2 (her2), erbb3 (her3), and erbb4 (her4). cancer patients erbb-1 (egfr) and erbb-2 (her-2) receptors are usually over-expressed or other changes occur on them. currently known human epidermal growth factor receptor -2 (erbb-2, her-2) is a clearer understanding human cancer gene which is closely related to breast cancer .its highly expression in breast cancer often precedes that it is easy to metastasize to lymph nodes and it is poorly differentiated , its prognosis is not good. with the in-depth study of her-2 , it has become one target molecule of the breast cancer-specific therapy.
the above information is edited by the chemicalbook of tian ye.
usage lapatinib ditosylate (gw572016, gw2016, tykerb, tyverb) is a potent egfr and erbb2 inhibitor with ic50 of 10.8 and 9.2 nm, respectively.
usage lapatinib, used in the form of lapatinib ditosylate, is a potent egfr and erbb2 inhibitor with ic50 of 10.8 and 9.2 nm, respectively.
usage antineoplastic, tyrosine kinase inhibitor

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Related Products

Related Keywords

Inquiry Cart 0